Login / Signup

Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes.

Sadia ZafarDafne Carolina Alves QuixabeiraTatiana Viktorovna KudlingVictor Cervera-CarrasconJoao Manuel SantosSusanna Grönberg-Vähä-KoskelaFang ZhaoPasi AronenCamilla HeiniöRiikka HavunenSuvi SorsaAnna KanervaAkseli E Hemminki
Published in: Cancer gene therapy (2020)
Oncolytic adenoviruses are promising cancer therapeutic agents. Clinical data have shown adenoviruses' ability to transduce tumors after systemic delivery in human cancer patients, despite antibodies. In the present work, we have focused on the interaction of a chimeric adenovirus Ad5/3 with human lymphocytes and human erythrocytes. Ad5/3 binding with human lymphocytes and erythrocytes was observed to occur in a reversible manner, which allowed viral transduction of tumors, and oncolytic potency of Ad5/3 in vitro and in vivo, with or without neutralizing antibodies. Immunodeficient mice bearing xenograft tumors showed enhanced tumor transduction following systemic administration, when Ad5/3 virus was bound to lymphocytes or erythrocytes (P < 0.05). In conclusion, our findings reveal that chimeric Ad5/3 adenovirus reaches non-injected tumors in the presence of neutralizing antibodies: it occurs through reversible binding to lymphocytes and erythrocytes.
Keyphrases